The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | New therapies for amyloidosis
Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, outlines the latest new therapies emerging from the multiple myeloma field for the treatment of amyloidosis. Dr Dispenzieri comments on the excitement surrounding venetoclax, a BCL-2 inhibitor which has now demonstrated promising results for amyloidosis treatment. Dr Dispenzieri also talks on daratumumab, a CD38-targeting IgG1k human monoclonal antibody, the only novel therapy to be FDA approved for the treatment of amyloidosis, and discusses the efficacy and safety profile of the proteasome inhibitor ixazomib and the immunomodulatory drug lenalidomide. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
